EA201692541A1 - Вакцины против вируса гриппа и их применения - Google Patents

Вакцины против вируса гриппа и их применения

Info

Publication number
EA201692541A1
EA201692541A1 EA201692541A EA201692541A EA201692541A1 EA 201692541 A1 EA201692541 A1 EA 201692541A1 EA 201692541 A EA201692541 A EA 201692541A EA 201692541 A EA201692541 A EA 201692541A EA 201692541 A1 EA201692541 A1 EA 201692541A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vaccines against
flu virus
against flu
methods
hemagglutinin
Prior art date
Application number
EA201692541A
Other languages
English (en)
Other versions
EA038400B1 (ru
Inventor
Антоньетта Импальяццо
Ян Вилем Мейберг
Катарина Радошевич
Мишель Вагнер
Чжаоцин Дин
Original Assignee
Янссен Вэксинс Энд Превеншн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692541(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Вэксинс Энд Превеншн Б.В. filed Critical Янссен Вэксинс Энд Превеншн Б.В.
Publication of EA201692541A1 publication Critical patent/EA201692541A1/ru
Publication of EA038400B1 publication Critical patent/EA038400B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

В предлагаемом изобретении обеспечиваются полипептиды стеблевого домена гемагглютинина вируса гриппа, способы получения полипептидов стеблевого домена гемагглютинина, композиции, содержащие их, вакцины, содержащие их, и способы их применения, в частности в выявлении, предупреждении и/или лечении гриппа.
EA201692541A 2014-07-10 2015-07-09 Полипептид стеблевого домена гемагглютинина вируса гриппа и его применение EA038400B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14176451 2014-07-10
US201462062746P 2014-10-10 2014-10-10
EP14195133 2014-11-27
PCT/EP2015/065661 WO2016005480A1 (en) 2014-07-10 2015-07-09 Influenza virus vaccines and uses thereof

Publications (2)

Publication Number Publication Date
EA201692541A1 true EA201692541A1 (ru) 2017-05-31
EA038400B1 EA038400B1 (ru) 2021-08-23

Family

ID=55063615

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692541A EA038400B1 (ru) 2014-07-10 2015-07-09 Полипептид стеблевого домена гемагглютинина вируса гриппа и его применение

Country Status (16)

Country Link
US (2) US10111944B2 (ru)
EP (2) EP3587442A1 (ru)
JP (1) JP6735269B2 (ru)
KR (1) KR102461538B1 (ru)
CN (1) CN106661091B (ru)
AU (1) AU2015286721B2 (ru)
BR (1) BR112017000257A2 (ru)
CA (1) CA2952351C (ru)
CL (1) CL2017000063A1 (ru)
EA (1) EA038400B1 (ru)
MX (1) MX2017000394A (ru)
MY (1) MY187261A (ru)
PE (1) PE20170290A1 (ru)
PH (1) PH12016502500A1 (ru)
SG (1) SG11201610443WA (ru)
WO (1) WO2016005480A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
BR112014012681A8 (pt) 2011-11-28 2017-06-20 Crucell Holland Bv polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica
NZ627796A (en) 2012-12-18 2017-07-28 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
MX369317B (es) 2013-05-30 2019-11-05 Janssen Vaccines & Prevention Bv Vacunas contra el virus de la influenza y sus usos.
AU2015286723B2 (en) 2014-07-10 2019-11-21 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EA038400B1 (ru) 2014-07-10 2021-08-23 Янссен Вэксинс Энд Превеншн Б.В. Полипептид стеблевого домена гемагглютинина вируса гриппа и его применение
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
HUE059545T2 (hu) 2018-01-23 2022-11-28 Janssen Vaccines & Prevention Bv Influenzavírus-vakcinák és alkalmazásaik
WO2021043869A1 (en) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
ES2934102T3 (es) 2009-05-11 2023-02-16 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden neutralizar el virus de la gripe H3N2 y usos de las mismas
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
JP5683752B2 (ja) 2011-07-14 2015-03-11 クルセル ホランド ベー ヴェー 系統グループ１及び系統グループ２のインフルエンザａ型ウイルス、並びにインフルエンザｂ型ウイルスを中和することが可能なヒト結合分子
BR112014012681A8 (pt) * 2011-11-28 2017-06-20 Crucell Holland Bv polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica
MX369317B (es) 2013-05-30 2019-11-05 Janssen Vaccines & Prevention Bv Vacunas contra el virus de la influenza y sus usos.
AU2015286723B2 (en) 2014-07-10 2019-11-21 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EA038400B1 (ru) 2014-07-10 2021-08-23 Янссен Вэксинс Энд Превеншн Б.В. Полипептид стеблевого домена гемагглютинина вируса гриппа и его применение

Also Published As

Publication number Publication date
PH12016502500A1 (en) 2017-03-22
CL2017000063A1 (es) 2017-12-15
PE20170290A1 (es) 2017-03-26
MX2017000394A (es) 2017-11-30
JP6735269B2 (ja) 2020-08-05
CN106661091A (zh) 2017-05-10
MY187261A (en) 2021-09-16
KR20170030590A (ko) 2017-03-17
JP2017521425A (ja) 2017-08-03
CN106661091B (zh) 2020-10-30
CA2952351C (en) 2023-10-17
SG11201610443WA (en) 2017-01-27
US10111944B2 (en) 2018-10-30
EP3166962A1 (en) 2017-05-17
US20170209564A1 (en) 2017-07-27
AU2015286721B2 (en) 2019-11-21
EP3166962B1 (en) 2019-08-21
CA2952351A1 (en) 2016-01-14
EP3587442A1 (en) 2020-01-01
AU2015286721A1 (en) 2016-12-22
WO2016005480A1 (en) 2016-01-14
EA038400B1 (ru) 2021-08-23
KR102461538B1 (ko) 2022-10-31
US10328144B2 (en) 2019-06-25
BR112017000257A2 (pt) 2017-10-31
US20190015500A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
BR112016030968A2 (pt) análogos de pridopidina, preparação e uso destes
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
HK1245776A1 (zh) 流感病毒複製抑制劑及其使用方法和用途
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
BR112016023833A2 (pt) compostos, composições, métodos e uso para tratar ou prevenir infecções por vírus da hepatite c
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
EA202091567A1 (ru) Химерные белки мти
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
BR112017005993A2 (pt) derivados de peptídeo inovadores e usos dos mesmos
ZA201700164B (en) Influenza virus vaccines and uses thereof
TR201402220A2 (tr) Hemaglütinin esteraz baskılama niteliği sergileyen pikroretosit türevlerini ihtiva eden bir kompozisyon ve bu kompozisyonun viral enfeksiyonların tedavisinde kullanımı.
TH1501007185A (th) ไวรัสและวัคซีน